QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

Core News & Articles

https://www.marijuanamoment.net/top-federal-drug-official-says-theres-tremendous-excitement-around-psych

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

 compass-pathways-reports-q1-cash-and-cash-equivalents-of-2629m

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million. The ...

 compass-pathways-announced-topline-results-from-an-open-label-phase-2-study-of-comp360-psilocybin-treatment-for-post-traumatic-stress-disorder-the-study-met-its-primary-safety-endpoint-and-available-secondary-efficacy-endpoints

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clin...

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

 compass-pathways-mindful-health-solutions-enter-research-collaboration-agreement-to-inform-development-of--scalable-and-cost-effective-delivery-model-for-comp360-psilocybin-treatment

This is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deli...

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.